| Issue Date | Title | Author(s) |
| 2012-01-01 | Defining refractory pain in cancer for clinicians and researchers | Currow, DC; Spruyt, O; Hardy, J |
| 2014-01-01 | Implementing practice change in chronic cancer pain management: Clinician response to a phase III study of ketamine | Hardy, JR; Spruyt, O; Quinn, SJ; Devilee, LR; Currow, DC |
| 2015-01-01 | Pharmacovigilance in hospice/palliative care: Net effect of gabapentin for neuropathic pain | Sanderson, C; Quinn, SJ; Agar, M; Chye, R; Clark, K; Doogue, M; Fazekas, B; Lee, J; Lovell, MR; Rowett, D; Spruyt, O; Currow, DC |
| 2016-09-01 | Pharmacovigilance in hospice/palliative care: Net effect of pregabalin for neuropathic pain | Sanderson, C; Quinn, SJ; Agar, M; Chye, R; Clark, K; Doogue, M; Fazekas, B; Lee, J; Lovell, MR; Rowett, D; Spruyt, O; Currow, DC |
| 2013-11-01 | Placebo and nocebo effects in randomized controlled trials: The implications for research and practice | Sanderson, C; Hardy, J; Spruyt, O; Currow, DC |
| 2018-05-02 | A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment | Hardy, J; Skerman, H; Glare, P; Philip, J; Hudson, P; Mitchell, G; Martin, P; Spruyt, O; Currow, D; Yates, P |
| 2012-10-10 | Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain | Hardy, J; Quinn, S; Fazekas, B; Plummer, J; Eckermann, S; Agar, M; Spruyt, O; Rowett, D; Currow, DC |
| 2021-01-01 | The Palliative Care-Promoting Access and Improvement of the Cancer Experience (PC-PAICE) Project in India: A Multisite International Quality Improvement Collaborative. | Lorenz, KA; Mickelsen, J; Vallath, N; Bhatnagar, S; Spruyt, O; Rabow, M; Agar, M; Dy, SM; Anderson, K; Deodhar, J; Digamurti, L; Palat, G; Rayala, S; Sunilkumar, MM; Viswanath, V; Warrier, JJ; Gosh-Laskar, S; Harman, SM; Giannitrapani, KF; Satija, A; Pramesh, CS; DeNatale, M |
